Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

FDA Clears Hologic R2(TM) DigitalNow(TM) HD Software Application
Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced that it has received Food and Drug Administration (FDA) clearance for its R2(TM) DigitalNow(TM) HD software application.
generic viagra online
709,000 Arkansans Are In Families That Will Spend More Than 10 Percent Of Their Income On Health Care In 2009
A report released by the consumer health organization Families USA spotlights a growing crisis among insured families, as rising health care costs devour a growing portion of their pre-tax income. Purchase zoloft to treat depression.
News of the day
In Prostate Cancer, Gene Activity Reveals Dynamic Stroma Microenvironment
As stroma - the supportive framework of the prostate gland- react to prostate cancer, changes in the expression of genes occur that induce the formation of new structures such as blood vessels, nerves and parts of nerves, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Clinical Cancer Research.
Medical Devices

Schering-Plough Announces Phase II And III Data For Corifollitropin Alfa

in ART procedures. Oral presentation at 25th European Society of Human Reproduction and Embryology (ESHRE) on June 29, 2009. Abstract no. O-005 2. Behr B,et al Corifollitropin alfa versus recombinant FSH treatment in controlled ovarian stimulation: equal efficacy in terms of oocyte and embryo quality. Oral presentation at 25th European Society of Human Reproduction and Embryology (ESHRE) on June 29, 2009. Abstract no O-003 3. Doody K et al, Puregon reference-"Success rates of a fixed rFSH/GnRH antagonist protocol are not affected by enodgenous LH levels. Oral presentation at 25th European Society of Human Reproduction and Embryology (ESHRE) on July 1, 2009. Abstract no. O-255 4. Ledger W et al, Two doses of corifollitropin alfa allow for similar exposure and ovarian response in patients weighing less than or equal to 60 kg and > 60 kg. Oral presentation at 25th European Society of Human Reproduction and Embryology (ESHRE) on July 1, 2009. Abstract no. O-282 5. Hillensjo T et al, Corifollitropin alfa versus recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Oral presentation at 25th European Society of Human Reproduction and Embryology (ESHRE) on June 29, 2009. Abstract no. O-004 6. Fatemi HM et al, The first pilot study with corifollitropin alfa in a long GnRH agonist protocol indicates the development of a large cohort of follicles during the first week of ovarian stimulation. Oral presentation at 25th European Society of Human Reproduction and Embryology (ESHRE) on July 1, 2009. Abstract no. O-283 7. Frequently Asked Questions About Infertility. American Society for Reproductive Medicine Web site. http://www.asrm.org/Patients/faqs.html. Accessed May 14, 2009 8. http://www.icsi.ws/about_infertility. Accessed May 14, 2009 9. Frequently Asked Questions; Questions about Infertility. Centre for Fertility and Reproductive Medicine. http://www.csmc.edu/3830.html. Accessed May 14, 2009 Schering-Plough

Pages: 1 [2] 


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009